Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,819 across all filing types
Latest filing 2021-08-18 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2021-08-18 English
6-K
Foreign Filer Report
2021-08-17 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement regarding a capital increase resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, and the resulting change in total share capital. This falls under the category of share issues or capital changes.
2021-08-17 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement regarding a capital increase resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, and the resulting change in total share capital. This falls directly under the definition of 'Share Issue/Capital Change' (SHA), as it describes a specific event involving the issuance of new shares and the subsequent change in the company's capital structure.
2021-08-17 English
6-K
Foreign Filer Report
2021-08-11 English
Report Publication Announcement 2021
Report Publication Announcement Classification · 95% confidence The document is an announcement from Genmab regarding their financial results for the first half of 2021. While it contains summary financial data, the document explicitly refers to an attached 'Interim Report' and provides a link to download the full report. According to the 'Menu vs Meal' rule, since this is a short announcement (under 5,000 characters of core content excluding boilerplate) that directs the reader to an attached full report, it is classified as a Report Publication Announcement (RPA). H1 2021
2021-08-11 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.